(NYSE: TAK) Takeda Pharmaceutical Co's forecast annual revenue growth rate of -0.45% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Takeda Pharmaceutical Co's revenue in 2025 is $29,988,259,705.On average, 2 Wall Street analysts forecast TAK's revenue for 2026 to be $47,627,574,618,596, with the lowest TAK revenue forecast at $47,491,048,545,874, and the highest TAK revenue forecast at $47,764,100,691,317. On average, 2 Wall Street analysts forecast TAK's revenue for 2027 to be $46,821,492,070,817, with the lowest TAK revenue forecast at $46,664,410,158,990, and the highest TAK revenue forecast at $46,978,573,982,644.
In 2028, TAK is forecast to generate $46,254,230,573,192 in revenue, with the lowest revenue forecast at $45,141,684,831,454 and the highest revenue forecast at $47,366,776,314,930.